巻号一覧
30 巻 (1999)
- 6 号 p. 755-
- 5 号 p. 729-
- 4 号 p. 65E-
- 3 号 p. 565-
- 2 号 p. 31E-
- 1 号 p. 1-
30 巻, 5 号
選択された号の論文の4件中1～4を表示しています
- |<
- <
- 1
- >
- >|
-
井上 郁夫, 片山 茂裕1999 年 30 巻 5 号 p. 729-740
発行日: 1999/09/30
公開日: 2010/06/28
ジャーナル フリーPDF形式でダウンロード (1736K) -
Akio FUJIMURA, Akio EBIHARA, Tatsuo SHIIGAI, Kazuyuki SHIMADA, Hitoshi ...1999 年 30 巻 5 号 p. 741-744
発行日: 1999/09/30
公開日: 2010/06/28
ジャーナル フリーObjective: To determine whether the severity and frequency of dry cough induced by enalapril, an angiotensin-converting enzyme (ACE) inhibitor, might be altered by changing its administration time.
Methods: Twenty-one patients with hypertension and three with chronic heart failure received enalapril (5 mg) once daily in the morning for more than 2 weeks and complained of persistent, non-productive dry cough. After the severity and frequency of cough were evaluated using a questionnaire, enalapril (5 mg) was given once daily in the evening for more than 2 weeks. At the end of this period, patients were asked to specify any changes in their cough during the evening treatment regimen, according to the following 5-point response scale: 1 (much worse), 2 (moderately worse), 3 (no change), 4 (moderately improved) and 5 (much improved).
Results: The severity of dry cough was attenuated [mean change (and 95% CI): 3.75 (3.37-4.13)] and the frequency was reduced [mean change: 3.79 (3.44-4.14)] after the administraiton time was changed to evening.
Conclusion: Dry cough is the most common adverse effect of ACE inhibitors. The present findings suggest that a chronopharmacological approach might ameliorate enalapril-induced dry cough and, consequently, improve QOL in treated patients.抄録全体を表示PDF形式でダウンロード (400K) -
川上 美由希, 平田 純生, 和泉 智, 濱澤 三恵子, 小泉 恩伶, 筆本 真由美, 別所 偉光, 加藤 禎一, 金 昌雄, 田中 一彦1999 年 30 巻 5 号 p. 745-747
発行日: 1999/09/30
公開日: 2010/06/28
ジャーナル フリーPDF形式でダウンロード (391K) -
上村 尚人, 角南 由紀子, 木村 美由紀, 古家 英寿, 浦江 明憲, 中野 真子1999 年 30 巻 5 号 p. 749-751
発行日: 1999/09/30
公開日: 2010/06/28
ジャーナル フリーA well designed clinical trial will provide useful information for therapeutic decision making and have a significant role in the accumulation of evidence, upon which clinicians can base daily medical practice. Thus, clinical trials are extremely important in evidencebased medicine. The goals of this discussion were to review the systemic problems in clinical research faced in Japan, and to propose actions to facilitate clinical trials that would provide evidence to benefit not only the Japanese society but also the patients worldwide. Japan lags behind European countries and the United States as far as the quantity and quality of clinical trials. Unfortunately, not many large clinical trials with true endpoint have been conducted in Japan. Japanese physicians have relied greatly upon the outcomes from clinical researches conduced in foreign countries. It must be clearly emphasized, however, that some clinical trials from foreign countries should be carefully interpreted when they are introduced into medical practice in one's particular community. Not only the differences in the epidemiological backgrounds or disease structures between races, but also those in medical environments including medical culture and economy may have a significant impact on the interpretation of the results of clinical trials. The discussion focused on the necessity of original clinical trials in Japan.抄録全体を表示PDF形式でダウンロード (357K)
- |<
- <
- 1
- >
- >|